Nadi Forough, Abdollahpour Esmat, Fallahi Babak, Aghaghazvini Leila, Alikhani Majid, Nejadhosseinian Mohammad, Faezi Seyedeh Tahereh
Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Nephrology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
BMC Rheumatol. 2024 Dec 18;8(1):70. doi: 10.1186/s41927-024-00440-4.
In patients with Systemic lupus erythematosus (SLE), osteonecrosis of various joints is a debilitating complication associated with the disease and its treatment, in which a considerable proportion of osteonecrosis may be asymptomatic. Recognizing the crucial role of early and timely detection, as well as appropriate management of asymptomatic osteonecrosis, in preventing joint destruction, we conducted a study to evaluate the prevalence of asymptomatic osteonecrosis in SLE patients who have already been diagnosed with symptomatic osteonecrosis. Additionally, we aimed to examine the relationship between proposed risk factors of osteonecrosis and the development of asymptomatic osteonecrosis.
In this cross-sectional study, Patients with recently diagnosed symptomatic osteonecrosis of at least one joint were selected by reviewing data from the digital medical record system of the Rheumatology Research Center. The patients underwent three-phase Single Photon Emission Computed Tomography (SPECT) bone scintigraphy to screen for other asymptomatic osteonecrotic joints. MRI was subsequently performed on the asymptomatic osteonecrotic sites for further diagnostic confirmation. The study evaluated the prevalence of asymptomatic osteonecrosis, the extent of joint involvement, the specific locations of osteonecrosis, the most commonly affected joints, and the risk factors for asymptomatic osteonecrosis.
Eight out of the 17 patients (47%) who participated in our research were found to have asymptomatic osteonecrosis. The most commonly affected joint without symptoms was the left knee (25%), while the most frequently affected joint with symptoms was the left hip (23.07%). The only statistically significant difference observed between patients with and without asymptomatic osteonecrosis in this study was the age at which the disease first appeared (p = 0.046) and this age was higher among patients with asymptomatic osteonecrosis.
Our research provides further evidence of the high incidence of asymptomatic osteonecrosis in individuals with SLE due to the nature of the disease and the frequent use of high-dose corticosteroids. It underscores the importance of early detection through whole-body SPECT bone scintigraphy and MRI, as well as prompt intervention in order to avert the incapacitating effects of osteonecrosis.
在系统性红斑狼疮(SLE)患者中,各种关节的骨坏死是一种与该疾病及其治疗相关的使人衰弱的并发症,其中相当一部分骨坏死可能是无症状的。认识到早期及时检测以及对无症状骨坏死进行适当管理在预防关节破坏中的关键作用,我们开展了一项研究,以评估已被诊断为有症状骨坏死的SLE患者中无症状骨坏死的患病率。此外,我们旨在研究骨坏死的潜在危险因素与无症状骨坏死发生之间的关系。
在这项横断面研究中,通过查阅风湿病研究中心数字病历系统的数据,选取近期诊断为至少一个关节有症状骨坏死的患者。患者接受三相单光子发射计算机断层扫描(SPECT)骨闪烁显像,以筛查其他无症状骨坏死关节。随后对无症状骨坏死部位进行磁共振成像(MRI)以进一步确诊。该研究评估了无症状骨坏死的患病率、关节受累程度、骨坏死的具体部位、最常受累关节以及无症状骨坏死的危险因素。
参与我们研究的17例患者中有8例(47%)被发现有无症状骨坏死。最常出现无症状的关节是左膝(25%),而最常出现有症状的关节是左髋(23.07%)。在本研究中,有和没有无症状骨坏死的患者之间观察到的唯一具有统计学意义的差异是疾病首次出现的年龄(p = 0.046),无症状骨坏死患者的这个年龄更高。
我们的研究进一步证明,由于疾病的性质以及高剂量糖皮质激素的频繁使用,SLE患者中无症状骨坏死的发生率很高。它强调了通过全身SPECT骨闪烁显像和MRI进行早期检测以及及时干预以避免骨坏死致残影响的重要性。